Daiichi Sankyo Limited

6 days ago · seekingalpha.com

Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript

6 days ago · businesswire.com

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026. “Strong revenue growth continues in the second quarter of fiscal year 2026, driven by Enhertu and Datroway. These medicines have received nine new approvals across multiple indications since last quarter, including same day breast cancer approvals in Japan and China, which will allow us to bring these medicines to more patients,” said Hiroyuki Okuz.

8 days ago · businesswire.com

MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinuation remains a pe.

15 days ago · businesswire.com

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO.

17 days ago · zacks.com

Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).

1 month ago · seekingalpha.com

Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript

1 month ago · reuters.com

AstraZeneca and Daiichi Sankyo have entered into ​a clinical collaboration with ‌Summit Therapeutics to test their cancer drug, Datroway, in ​combination with Summit's ​ivonescimab across multiple tumour types, ⁠including lung and breast ​cancers.

1 month ago · reuters.com

Merck ​and Daiichi ‌Sankyo have ​voluntarily ​withdrawn their ⁠US ​application ​seeking accelerated approval ​for ​their experimental lung ‌cancer ⁠therapy, the ​drugmakers ​said ⁠on Friday.

1 month ago · reuters.com

Malaysia's IHH Healthcare said on Thursday its subsidiary has appealed ​a Tokyo court's dismissal of its damages claim ‌against Daiichi Sankyo over the unit's acquisition of a stake in India's Fortis Healthcare.

2 months ago · businesswire.com

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimat.